Search

Your search keyword '"Medaer, R."' showing total 107 results

Search Constraints

Start Over You searched for: Author "Medaer, R." Remove constraint Author: "Medaer, R." Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
107 results on '"Medaer, R."'

Search Results

1. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

4. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

5. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

10. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

12. Health-related quality of life in multiple sclerosis: Effects of natalizumab

13. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

14. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis

15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

16. Rate of pregnancy-related relapse in multiple sclerosis

17. The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis

18. Long-term follow up of glatiramer acetate compassionate use in Belgium.

23. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis

31. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing--remitting multiple sclerosis.

36. Risks of multiple sclerosis in relatives of patients in Flanders, Belgium

39. classics in neurology

41. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing–remitting multiple sclerosis

45. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.

46. Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.

47. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.

48. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates.

49. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.

50. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.

Catalog

Books, media, physical & digital resources